PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
Fiche publication
Date publication
juin 2017
Journal
International journal of molecular sciences
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
In the last few decades, a better knowledge of the inflammatory pathways involved in the pathogenesis of Inflammatory Bowel Disease (IBD) has promoted biological therapy as an important tool to treat IBD patients. However, in spite of a wider spectrum of biological drugs, a significant proportion of patients is unaffected by or lose their response to these compounds, along with increased risks of infections and malignancies. For these reasons there is an urgent need to look for new pharmacological targets. The novel Phosphodiesterase 4 (PDE4) inhibitors have been recently introduced as new modulators of intracellular signals and gene transcription for the treatment of IBD.
Mots clés
Inflammatory Bowel Disease, PDE4, apremilast
Référence
Int J Mol Sci. 2017 Jun 15;18(6):